Sunshine Biopharma (SBFM) Restructuring Costs (2023 - 2026)

Sunshine Biopharma has reported Restructuring Costs for 4 years, with the latest figure at $871608.0 in Q1 2026.

• For the quarter ending Q1 2026, Restructuring Costs fell 5.86% year-over-year to $871608.0; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (up 23.89% YoY), and the FY2025 full-year result was $3.9 million, up 24.26% from the prior year.
• Restructuring Costs for Q1 2026 stood at $871608.0, down from $1.5 million in the prior quarter.
• The five-year high for Restructuring Costs was $1.5 million in Q4 2025, with the low at $530334.0 in Q3 2024.
• Historically, Restructuring Costs has averaged $823777.3 across 4 years, with a median of $806605.0 in 2025.
• Annual changes were most pronounced in 2025 — Restructuring Costs jumped 67.48% — and 2026, when it declined 5.86%.
• Sunshine Biopharma's Restructuring Costs stood at $720297.0 in 2023, then grew by 25.79% to $906056.0 in 2024, then jumped by 67.48% to $1.5 million in 2025, then tumbled by 42.56% to $871608.0 in 2026.
• The last three Restructuring Costs figures came in at $871608.0 (Q1 2026), $1.5 million (Q4 2025), and $614661.0 (Q3 2025), per Business Quant data.